AU1386301A - Polymorphic forms of sertraline hydrochloride - Google Patents

Polymorphic forms of sertraline hydrochloride

Info

Publication number
AU1386301A
AU1386301A AU13863/01A AU1386301A AU1386301A AU 1386301 A AU1386301 A AU 1386301A AU 13863/01 A AU13863/01 A AU 13863/01A AU 1386301 A AU1386301 A AU 1386301A AU 1386301 A AU1386301 A AU 1386301A
Authority
AU
Australia
Prior art keywords
polymorphic forms
sertraline hydrochloride
sertraline
hydrochloride
polymorphic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU13863/01A
Other languages
English (en)
Inventor
Andreas Burkhard
Hans-Jorg Kirner
Claudia Marcolli
Regine Peter
Franz Schwarzenbach
Martin Szelagiewicz
Paul Adriaan Van Der Schaaf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Schweiz AG
Original Assignee
Ciba Spezialitaetenchemie Holding AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8243113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU1386301(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ciba Spezialitaetenchemie Holding AG filed Critical Ciba Spezialitaetenchemie Holding AG
Publication of AU1386301A publication Critical patent/AU1386301A/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU13863/01A 1999-10-29 2000-10-23 Polymorphic forms of sertraline hydrochloride Abandoned AU1386301A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99810981 1999-10-29
EP99810981 1999-10-29
PCT/EP2000/010416 WO2001032601A1 (en) 1999-10-29 2000-10-23 Polymorphic forms of sertraline hydrochloride

Publications (1)

Publication Number Publication Date
AU1386301A true AU1386301A (en) 2001-05-14

Family

ID=8243113

Family Applications (1)

Application Number Title Priority Date Filing Date
AU13863/01A Abandoned AU1386301A (en) 1999-10-29 2000-10-23 Polymorphic forms of sertraline hydrochloride

Country Status (17)

Country Link
US (2) US6872853B1 (enExample)
EP (1) EP1224160B1 (enExample)
JP (1) JP2003513062A (enExample)
CN (1) CN1384816A (enExample)
AR (1) AR026293A1 (enExample)
AT (1) ATE409684T1 (enExample)
AU (1) AU1386301A (enExample)
CA (1) CA2387135A1 (enExample)
DE (1) DE60040406D1 (enExample)
HU (1) HUP0203559A3 (enExample)
IL (2) IL149050A0 (enExample)
MX (1) MXPA02004255A (enExample)
MY (1) MY141509A (enExample)
TR (1) TR200201146T2 (enExample)
TW (1) TWI260315B (enExample)
WO (1) WO2001032601A1 (enExample)
ZA (1) ZA200203254B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1630156A1 (en) * 1998-11-27 2006-03-01 Teva Pharmaceutical Industries Ltd Sertraline hydrochloride polymorphs
EP1133459B1 (en) * 1998-11-27 2006-01-11 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride form v
US6500987B1 (en) * 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
US6495721B1 (en) 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
US7442838B2 (en) * 1999-10-29 2008-10-28 Ciba Specialty Chemicals Corp. Polymorphic forms of sertraline hydrochloride
US20050119351A1 (en) * 1999-10-29 2005-06-02 Van Der Schaaf Paul A. Polymorphic forms of sertraline hydrochloride
EP1774965A3 (en) * 1999-12-21 2007-10-10 Teva Pharmaceutical Industries Ltd Novel sertraline hydrochloride polymorph, processes for preparing them, compositions containing them and methods of using them
PL356452A1 (en) * 1999-12-21 2004-06-28 Teva Pharmaceutical Industries Ltd. Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
IN192343B (enExample) * 2000-05-26 2004-04-10 Ranbaxy Lab Ltd
WO2002096859A1 (en) * 2001-05-31 2002-12-05 Orion Corporation Fermion Process for preparing sertraline hydrochloride polymorphic form ii
CA2483569A1 (en) * 2002-04-29 2003-11-13 Tamar Nidam Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
EP1527617A4 (en) * 2002-06-27 2006-01-04 Interdigital Tech Corp PAIR EXCHANGE TO PAIR USER EQUIPMENT MEASUREMENT INFORMATION BETWEEN RADIO NETWORK CONTROLLERS
US7186863B2 (en) 2003-05-23 2007-03-06 Transform Pharmaceuticals, Inc. Sertraline compositions
EP1682483B1 (en) * 2003-11-04 2010-05-26 Cipla Ltd. Process for the preparation of polymorphs of sertraline hydrochloride
EP1711493A2 (en) * 2004-02-06 2006-10-18 CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement Crystalline forms of zolmitriptan
WO2007008317A2 (en) * 2005-06-09 2007-01-18 Teva Pharmaceutical Industries Ltd. Process for preparation of sertraline hydrochloride form i
US7518019B2 (en) 2006-06-01 2009-04-14 Hetero Drugs Limited Processes for preparing sertraline hydrochloride crystalline forms
CA2594198A1 (en) * 2007-07-20 2009-01-20 Apotex Pharmachem Inc. A novel process for the preparation of sertraline hydrochloride form ii
US9993793B2 (en) 2010-04-28 2018-06-12 The Procter & Gamble Company Delivery particles
US9186642B2 (en) 2010-04-28 2015-11-17 The Procter & Gamble Company Delivery particle
MX2013010981A (es) 2011-04-07 2013-10-30 Procter & Gamble Composiciones acondicionadoras con deposito mejorado de microcapsulas de poliacrilato.
CN103458858B (zh) 2011-04-07 2016-04-27 宝洁公司 具有增强的聚丙烯酸酯微胶囊的沉积的洗发剂组合物
CN103458859A (zh) 2011-04-07 2013-12-18 宝洁公司 具有增强的聚丙烯酸酯微胶囊的沉积的个人清洁组合物
CN105061217A (zh) * 2015-06-30 2015-11-18 徐静 枸橼酸舍曲林的2种晶型及其制备方法
MX2023004231A (es) 2020-10-16 2023-04-21 Procter & Gamble Composiciones de producto de consumo que comprenden una poblacion de encapsulados.
MX2023004232A (es) 2020-10-16 2023-04-21 Procter & Gamble Composiciones de productos de consumo con al menos dos poblaciones de encapsulados.
US12486478B2 (en) 2020-10-16 2025-12-02 The Procter & Gamble Company Consumer products comprising delivery particles with high core:wall ratios
CN112552188B (zh) * 2020-12-17 2023-07-28 山西仟源医药集团股份有限公司 盐酸舍曲林晶型i的制备方法
CN113588626B (zh) * 2021-08-24 2024-05-24 上海师范大学 一种苯丙氨酸对映体的拉曼光谱检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US5082970A (en) 1991-03-06 1992-01-21 Pfizer Inc. Process for recycling amine isomer
GB9114947D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5734083A (en) * 1996-05-17 1998-03-31 Torcan Chemical Ltd. Sertraline polymorph
HU222341B1 (hu) 1996-12-18 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Eljárás sertralin előállítására és az eljárásban alkalmazott intermedier
EP0928784B1 (en) 1997-12-11 2002-06-12 TORCAN CHEMICAL Ltd Sertraline polymorph having improved water solubility
HUP0101322A3 (en) 1998-03-18 2002-06-28 Ciba Sc Holding Ag Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines
JP2000026378A (ja) 1998-07-03 2000-01-25 Sumika Fine Chemicals Co Ltd 塩酸セルトラリンの製法
US6500987B1 (en) 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
EP1133459B1 (en) * 1998-11-27 2006-01-11 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride form v
US6495721B1 (en) 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
PL356452A1 (en) 1999-12-21 2004-06-28 Teva Pharmaceutical Industries Ltd. Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them

Also Published As

Publication number Publication date
US6939992B2 (en) 2005-09-06
HUP0203559A2 (hu) 2003-03-28
US6872853B1 (en) 2005-03-29
HUP0203559A3 (en) 2008-01-28
MXPA02004255A (es) 2002-10-17
ATE409684T1 (de) 2008-10-15
EP1224160B1 (en) 2008-10-01
JP2003513062A (ja) 2003-04-08
US20040132828A1 (en) 2004-07-08
ZA200203254B (en) 2003-07-22
WO2001032601A1 (en) 2001-05-10
IL149050A0 (en) 2002-11-10
TR200201146T2 (tr) 2004-12-21
MY141509A (en) 2010-05-14
CA2387135A1 (en) 2001-05-10
DE60040406D1 (de) 2008-11-13
IL149050A (en) 2007-03-08
AR026293A1 (es) 2003-02-05
EP1224160A1 (en) 2002-07-24
TWI260315B (en) 2006-08-21
CN1384816A (zh) 2002-12-11

Similar Documents

Publication Publication Date Title
AU1386301A (en) Polymorphic forms of sertraline hydrochloride
AU7556800A (en) Amine derivatives
AU4033400A (en) Indirect registration of elements on web-derived product
AUPQ407699A0 (en) Aminoalcohol derivatives
AU1234002A (en) Crystalline forms of venlafaxine hydrochloride
AU2001256595A1 (en) Novel amorphous form of sertraline hydrochloride
AU1548101A (en) Sphingosine derivatives
AU6624000A (en) Recrystallization process
AU4604000A (en) Amorphous form of fexofenadine hydrochloride
AU5632300A (en) Methods of inhibiting muscle atrophy
AUPQ319899A0 (en) Amide compounds
AU2001266689A1 (en) 4-benzyl-2-hydroxy-1,4-oxazin-3-one and polymorphic forms thereof
AU5404500A (en) Reductive amination of aldehydes
AU1601801A (en) Methods of preparing crna
HUP0001558A3 (en) Process for the preparation of pirlindole hydrochloride
AU1724201A (en) Process for the preparation of fluoxetine hydrochloride
AUPQ142599A0 (en) New amide compounds
AU2002353803A1 (en) Direct resolution of racemic threo-methylphenidate hydrochloride
AU7990000A (en) Neuraminidase inhibitors
AU6481799A (en) Process for the preparation of paroxetine hydrochloride
AU1396400A (en) Process for the preparation of paroxetine hydrochloride
AU2003300814A1 (en) Polymorphic forms of ziprasidone and its hydrochloride
AU2003274608A1 (en) Process for preparation of polymorphic form of sertraline hydrochloride
AU1580101A (en) Indazolyloxy propanolamines for improving livestock production
AUPQ293099A0 (en) Recrystallization of semiconductor material

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase